【Adimmune】March 2026 Revenue NT$65 Million (YoY +2102.7%)
Adimmune's revenue for March 2026 was NT$65 million, a staggering increase of +2102.7% year-over-year. The company is in the Biotechnology and Medical Care industry.
📋 Article Processing Timeline
- 📰 Published: March 1, 2026 at 09:00
- 🔍 Collected: April 12, 2026 at 16:30 (1015h 30m after Published)
- 🤖 AI Analyzed: April 12, 2026 at 21:27 (4h 57m after Collected)
Company Ticker: 4142
Company Name: Adimmune
Industry: Biotechnology and Medical Care
Data Month: 2026-03
Monthly Revenue: 65,485 thousand TWD (65 million)
Year-over-Year Change: +2102.7%
Company Name: Adimmune
Industry: Biotechnology and Medical Care
Data Month: 2026-03
Monthly Revenue: 65,485 thousand TWD (65 million)
Year-over-Year Change: +2102.7%
FAQ
How was Adimmune's revenue in March 2026?
It was TWD 65.48 million, a record growth of +2102.7% year-over-year.
Why did Adimmune's revenue surge so much?
This is because revenue in the same month last year was extremely low, and revenue from vaccine shipments and contract manufacturing was recognized this month. The fact that there was revenue is more important than the growth rate figure itself.
Is Adimmune's business stable?
Monthly revenue fluctuates significantly, but this is characteristic of a business that produces and ships based on contracts. It needs to be evaluated on a quarterly or full-year basis.